CTRI/2019/06/019842进行中（未招募）未知
Ornithine L-Aspartate in Treatment of Overt Hepatic Encephalopathy in Patients with Cirrhosis: A Double-Blind Randomized Controlled Trial - LOLA-HE
Dr Shalimar0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1) Patients with Overt HE (more than grade II)
排除标准
- •1)Age < 18 and > 65 years
- •2)Acute liver failure
- •3)Serum creatinine > 1.5
- •4)Active alcohol consumption over the past 4 weeks
- •5)Infections other than SBP, e.g. pneumonia, frank sepsis
- •6)Ileus, intestinal obstruction
- •7)Hepatocellular carcinoma
- •8)Advanced cardiac or pulmonary disease
- •9)Underlying chronic kidney disease
- •10)Associated psychiatric illness
- •11)Pregnant or lactating women
- •12)Metabolic encephalopathy
- •13)Degenerative neurological disease
研究者
相似试验
已完成
4 期
L-ornithine L-aspartate in Overt Hepatic EncephalopathyCirrhosis of LiverHepatic EncephalopathyNCT01722578Dayanand Medical College and Hospital200
招募中
4 期
Role of L-Ornithine L-Aspartate in improving acute encephalopathy (altered sensorium) in patients with Liver CirrhosisCTRI/2013/02/003360Department of Gastroenterology164
招募中
不适用
Plasmapheresis plus LOLA in liver failure of children.CTRI/2023/02/049867Institute of Liver and Biliary Sciences
Unknown
4 期
Therapeutic Efficacy of Oral L-Ornithine-L-Aspartate on Minimal EncephalopathyHepatic EncephalopathyNCT00896831Hospital de Clinicas de Porto Alegre96
已完成
不适用
Oral L-Carnitine Treatment in Hepatic Encephalopathyhepatic encephalopathyJPRN-UMIN000009761Kurashiki Central Hospital20